(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 19 October 2000 (19.10.2000)

PCT

(10) International Publication Number WO 00/62070 A3

(51) International Patent Classification⁷: G01N 33/574, 33/573

(21) International Application Number: PCT/DK00/00170

(22) International Filing Date: 10 April 2000 (10.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PA 1999 00476

9 April 1999 (09.04.1999) DK

(71) Applicants and

(72) Inventors: HOLTEN-ANDERSEN, Mads [DK/DK]; Koldinggade 18, st.th., DK-2100 Copenhagen Ø (DK). STEPHENS, Ross, W. [AU/AU]; Unit 11 "Sandalyn", 43 Ijong Street, Braddon, ACT 2612 (AU). NIELSEN, Hans, Jørgen [DK/DK]; Ved Hjortekæret 17, DK-2800 Lyngby (DK). CHRISTENSEN, Ib, Jarle [DK/DK]; Rytterstien 8, DK-3400 Hillerød (DK). BRÜNNER, Nils [DK/DK]; Brodersens Allé 1, DK-2900 Hellerup (DK).

- (74) Agent: PLOUGMANN, VINGTOFT & PARTNERS A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

With international search report.

[Continued on next page]

(54) Title: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER

TIMP-1 levels (µg/L, log scale) in EDTA plasma from different patient groups compared to healthy donor samples.



(57) Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. Free and total TIMP-1 as well as TIMP-1:MP-9 complex may be measured. Combining these measurements with other cancer marker levels is also mentioned.



00/62070 A3